摘要
目的探讨CA125、CA199、CEA、AFP诊断女性盆腔包块的临床意义。方法收集盆腔包块住院病人208例,运用微粒子酶联免疫法(MEIA)测定术前1周血清CA125、CA199、CEA含量,采用放免法测定AFP含量。结果(1)盆腔恶性包块CA125、CA199水平均高于良性包块,尤其是CA125水平明显增高,良恶性包块中CA125的阳性率分别为36.3%、76%,差异有显著性。但CEA、AFP阳性率均较低。(2)子宫肌腺症、子宫内膜异位症CA125阳性率分别为74.4%、58.1%,均高于其它良性包块,差异有显著性。结论CA125是较理想的盆腔肿瘤标志物,CEA运用价值不大。
Aim To study the clinical value of CA125 , CA199, CEA and AFP in diagnosis of female pelvic mass. Method During one week before operation, the serum from 208 patients suffering from pelvic masses were assayed for CA125 , CA199 , CEA by Micropartical enzyme immunoassay（MEIA） and for AFP by radio immunoassay（RIA）. Results （ 1 ） CA125 and CA199 were higher in malignant mass than in benign mass,particularly CA125 The CA199 positive rates in maligant mass and benign mass were 36.3% ,76.0% respectively,but CEA, AFP positive rates were low. （2） The CA125 positive rates in endometrioma and endometriosis were 74.36% ,58.14% respectively and were higher than else benign masses. So the CA125 had differential diagnosis value. Conclusion The CA125 is an appropriate marker in diffrentiating pelvic masses. Clinical value of CEA is limited.
出处
《安徽医药》
CAS
2007年第1期56-57,共2页
Anhui Medical and Pharmaceutical Journal
